Pyxis Oncology Will Acquire Apexigen In An All-Stock Transaction For An Implied Value Of $0.64/Apexigen Share
Portfolio Pulse from Benzinga Newsdesk
Pyxis Oncology is set to acquire Apexigen in an all-stock transaction, valuing Apexigen shares at $0.64 each.
May 24, 2023 | 10:48 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Apexigen shareholders will receive Pyxis Oncology shares in an all-stock transaction, valuing Apexigen shares at $0.64 each.
The acquisition news directly impacts Apexigen as its shareholders will receive Pyxis Oncology shares. The implied value of $0.64 per share may not significantly affect the stock price in the short term, as the market will likely have already priced in the acquisition news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Pyxis Oncology is acquiring Apexigen in an all-stock transaction, valuing Apexigen shares at $0.64 each.
The acquisition news directly impacts Pyxis Oncology as it is acquiring Apexigen in an all-stock transaction. The short-term impact on the stock price may be neutral, as the market will likely have already priced in the acquisition news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100